R & D

Bristol Myers Squibb Announces LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination Significantly Improves Progression-Free Survival vs. Opdivo (nivolumab) in Patients with Previously Untreated Metastatic or Unresectable Melanoma

 This material is intended to notify the press release issued on May19 (local time) by Bristol Myers Squibb, our license partner for Opdivo.
 Please click for the original press release.